Price regulation associated with the Prostheses List Framework, with particular reference to:

1. the operation of relevant legislative and regulatory instruments;
2. opportunities for creating a more competitive basis for the purchase and reimbursement of prostheses;
3. the role and function of the Prostheses List Advisory Committee and its subcommittees;
4. the cost of medical devices and prostheses for privately insured patients versus public hospital patients and patients in other countries;
5. the impact the current Prostheses List Framework has on the affordability of private health insurance in Australia;
6. the benefits of reforming the reference pricing system with Australian and international benchmarks;
7. the benefits of any other pricing mechanism arrangements, including but not limited to those adopted by the Pharmaceutical Benefits Scheme, such as:
   1. mandatory price disclosure,
   2. value-based pricing, and
   3. reference pricing;
8. price data and analytics to reveal the extent of, and where costs are being generated within, the supply chain, with a particular focus on the device categories of cardiac, Intra Ocular Lens Systems, hips, knees, spine and trauma;
9. any interactions between Government decision-making and device manufacturers or stakeholders and their lobbyists;
10. any implications for prostheses recipients of the National Disability Insurance Scheme transition period; and
11. other related matters.